Table of Contents
1
UI - 11964043
AU - Bamberger AM; Kappes H; Methner C; Rieck G; Brummer J; Wagener C; Loning
TI -
T; Milde-Langosch K
Expression of the adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) in
breast cancer is associated with the expression of the tumor-suppressor
genes Rb, Rb2, and p27.
SO - Virchows Arch 2002 Feb;440(2):139-44
AD - Department of Gynecopathology, Institute of Pathology, University
Hospital Eppendorf, Hamburg, Germany. abamberger@uke.uni-hamburg.de
The adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) is not only involved
in maintaining normal tissue architecture, but also acts as a tumor
suppressor in several experimental systems where loss of CEACAM1
expression results in enhanced tumor-cell growth and tumorigenicity. In
order to further analyze the role of CEACAM1 in the development of
breast cancer, we performed Western-blot analysis and
immunohistochemistry with highly specific monoclonal antibodies in a
cohort of 68 mammary carcinomas which had also been analyzed for
expression of cell-cycle regulatory proteins cyclin D1, cyclin E, p16,
p21, p27, Rb, and Rb2, as well as for steroid hormone receptor status,
Ki67, and HER2/neu immunoreactivity. High CEACAM1 protein expression as
found using both methods correlated significantly with expression of the
retinoblastoma proteins Rb (P=0.004 and 0.013) and Rb2/p130 (P=0.003 and
0.007). In addition, we found a weak association of CEACAM1 expression
with p27 protein levels (P=0.087 and 0.039), but with none of the other
analyzed parameters. These results indicate the possibility of a
functional link between cell-adhesion molecules and cell-cycle
regulation that might play an important role in the development of
mammary carcinomas.
2
UI - 11920736
AU - Gugger M; Burckhardt E; Kappeler A; Hirsiger H; Laissue JA; Mazzucchelli
TI -
L
Quantitative expansion of structural genomic alterations in the spectrum
of neuroendocrine lung carcinomas.
SO - J Pathol 2002 Apr;196(4):408-15
AD - Institute of Pathology, University of Bern, Bern, Switzerland.
The pathogenesis and interrelationships of neuroendocrine lung
carcinomas are not well understood. Tissue macro-arrays prepared from
surgical resection specimens from 35 patients with typical carcinoid
(TC), six with atypical carcinoid (AC), 13 with large cell
neuroendocrine carcinoma (LCNEC), and 15 with small cell lung carcinoma
(SCLC) were investigated by fluorescence in situ hybridization (FISH)
and immunohistochemistry. Hybridizations with locus-specific DNA probes
demonstrated a high incidence of deletion for the tumour suppressor
genes p53 and retinoblastoma (Rb), and for the oncogene cyclin D1,
comparable in all carcinoma types. Similarly, an increase of DNA copy
number for the Her-2/neu and c-myc oncogenes was noted in all neoplasms.
A more detailed quantitative analysis of the results, however,
demonstrated increasing numbers of cells harbouring these genomic
alterations, from low-grade TC to highly malignant SCLC, with the
exception of cyclin D1 deletion. Mutations of the p53 and Rb genes, as
assayed by immunohistochemical studies, were observed at high incidence
in high-grade carcinomas, compared with a low incidence in the low-grade
carcinomas. Conversely, in all carcinoma types, neither membrane-bound
Her-2/neu nor nuclear cyclin D1 was detected. It is concluded that
structural genomic alterations are frequent in neuroendocrine lung
carcinomas and that their occurrence may be underestimated by
immunohistochemical studies alone. The quantitative expansion of the Rb,
p53, c-myc, and Her-2/neu alterations towards high-grade carcinomas
suggests common pathogenetic mechanisms in the spectrum of these
neoplasms. Copyright 2002 John Wiley & Sons, Ltd.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home